Brain cancer is an aggressive type of cancer that starts developing in the brain. There are many types of spinal cord and brain tumors, which can be either malignant or benign. Malignant brain tumors often grow and spread rather quickly into other tissues. The latest data from the National Cancer Institute shows that this year more than 24,000 individuals will be diagnosed with brain cancer and other cancers of the nervous system in America. SEER estimates that of this number, close to 19,000 individuals will succumb to this fatal disease, making up roughly 3% of all cancer deaths in the United States.
May is Brain Cancer Awareness month, so in an effort to raise more awareness about this disease, we look at some of the advancements made in the research and treatment of brain cancer. For starters, researchers have found that using low-intensity pulsed ultrasound in conjunction with IV microbubbles administration may improve the delivery of albumin-bound carboplatin and paclitaxel via the blood-brain barrier. Studies have also found that adding copper and disulfiram to chemotherapy does not cause a substantial increase in survival for patients suffering from recurrent glioblastoma.
One new study has determined that the maximal resection of low-grade gliomas following diagnosis may increase survival time. This study’s findings were reported in the “Journal of Clinical Oncology.”
Research by Northwest Therapeutics has discovered that adding a personalized immune therapy vaccine called DCVax-L, which is manufactured from antigens extracted from a tumor sample and a patient’s immune cells, to conventional cancer care extended how long glioblastoma patients could survive. Scientists have also developed an AI algorithm that utilizes computational analysis to identify potential therapeutic targets for aggressive cancer types such as glioblastoma multiforme. In addition, a separate team of scientists has also developed a pressurized pump that can be implanted into the body of a patient with glioblastoma to help circumvent the blood-brain barrier and direct chemotherapy to the location of recurrent tumors.
Furthermore, trials conducted by Day One Biopharmaceuticals have demonstrated that the company’s Day101 monotherapy, Tovorafenib, produced a response in almost two-thirds of patients with progressive or recurrent pediatric low-grade glioma.
In other news, the Food and Drug Administration also approved dabrafenib with trametinib for children with previously untreated low-grade glioma who need systemic therapy and have BRAF V600E mutations. Trametinib (Mekinist, Novartis) is a MEK1/2 inhibitor while Dabrafenib (Tafinlar, Novartis) is a BRAF inhibitor. It should be noted that this approval applies to children aged one year and older.
As more for-profit enterprises such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) press on with their efforts to develop better drugs to combat different kinds of brain cancer, the future could get brighter for patients diagnosed with these conditions.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
